000119860 001__ 119860
000119860 005__ 20240319081012.0
000119860 0247_ $$2doi$$a10.3389/fphar.2022.980391
000119860 0248_ $$2sideral$$a130591
000119860 037__ $$aART-2022-130591
000119860 041__ $$aeng
000119860 100__ $$0(orcid)0000-0002-7194-8275$$aMalo, Sara$$uUniversidad de Zaragoza
000119860 245__ $$aPatterns of statin adherence in primary cardiovascular disease prevention during the pandemic
000119860 260__ $$c2022
000119860 5060_ $$aAccess copy available to the general public$$fUnrestricted
000119860 5203_ $$aBackground: Study of medication adherence patterns can help identify patients who would benefit from effective interventions to improve adherence. Objectives: To identify and compare groups of statin users based on their adherence patterns before and during the COVID-19 pandemic, to characterize the profile of users in each group, and to analyze predictors of distinct adherence patterns.Methods: Participants of the CARhES (CArdiovascular Risk factors for HEalth Services research) cohort, comprising individuals aged >16 years, residing in Aragón (Spain), with hypertension, diabetes mellitus and/or dyslipidemia, took part in this observational longitudinal study. Individuals who began statin therapy during January–June 2019 were selected and followed up until June 2021. Those with a cardiovascular event before or during follow-up were excluded. Data were obtained from healthcare system data sources. Statin treatment adherence during the implementation phase was estimated bimonthly using the Continuous Medication Availability (CMA9) function in the AdhereR package. Group-based trajectory models were developed to group statin users according to their adherence pattern during July 2019–June 2021. Group characteristics were compared and predictors of each adherence pattern were analyzed using multinomial logistic regression.Results: Of 15,332 new statin users, 30.8% had a mean CMA9 ≥80% for the entire study period. Four distinct adherence patterns were identified: high adherence (37.2% of the study population); poor adherence (35.6%); occasional use (14.9%); and gradual decline (12.3%). The latter two groups included users who showed a change in adherence (increase or decrease) during the pandemic emergence. Users with suboptimal adherence were likely to be younger, not pensioners, not institutionalized, with low morbidity burden and a low number of comorbidities. Female sex and switching between statins of different intensity increased the likelihood of belonging to the occasional use group, in which improved adherence coincided with the pandemic. Conclusion: We identified four distinct adherence patterns in a population of new statin users; two of them modified their adherence during the pandemic. Characterization of these groups could enable more effective distribution of resources in future similar crisis and the routine implementation of patient-centered interventions to improve medication adherence.
000119860 536__ $$9info:eu-repo/grantAgreement/ES/DGA-GRISSA/B09-20R
000119860 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000119860 590__ $$a5.6$$b2022
000119860 592__ $$a1.064$$b2022
000119860 591__ $$aPHARMACOLOGY & PHARMACY$$b44 / 278 = 0.158$$c2022$$dQ1$$eT1
000119860 593__ $$aPharmacology (medical)$$c2022$$dQ1
000119860 593__ $$aPharmacology$$c2022$$dQ1
000119860 594__ $$a6.3$$b2022
000119860 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000119860 700__ $$0(orcid)0000-0003-1647-3462$$aMaldonado, Lina$$uUniversidad de Zaragoza
000119860 700__ $$0(orcid)0000-0002-6671-5661$$aRabanaque, María José$$uUniversidad de Zaragoza
000119860 700__ $$0(orcid)0000-0002-5440-1710$$aGimeno-Miguel, Antonio
000119860 700__ $$0(orcid)0000-0002-5064-3763$$aCastel-Feced, Sara$$uUniversidad de Zaragoza
000119860 700__ $$aLallana, María Jesús
000119860 700__ $$0(orcid)0000-0001-7293-701X$$aAguilar-Palacio, Isabel$$uUniversidad de Zaragoza
000119860 7102_ $$14014$$2623$$aUniversidad de Zaragoza$$bDpto. Economía Aplicada$$cÁrea Métodos Cuant.Econ.Empres
000119860 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000119860 773__ $$g13, 980391 (2022), 1-11$$pFront. pharmacol.$$tFrontiers in Pharmacology$$x1663-9812
000119860 8564_ $$s960823$$uhttps://zaguan.unizar.es/record/119860/files/texto_completo.pdf$$yVersión publicada
000119860 8564_ $$s2215076$$uhttps://zaguan.unizar.es/record/119860/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000119860 909CO $$ooai:zaguan.unizar.es:119860$$particulos$$pdriver
000119860 951__ $$a2024-03-18-15:12:48
000119860 980__ $$aARTICLE